Last updated on January 2019

A Phase 2/3 Study Investigating The Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged Greater Than Or Equal To 6 Months to Less Than 6 Years With Severe Atopic Dermatitis


Brief description of study

The primary objective for part A of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab administered as a single dose in pediatric patients, 6 months to less than 6 years of age with severe atopic dermatitis (AD).

The primary objective for part B of the study is to demonstrate the efficacy of multiple doses of dupilumab over 16 weeks of treatment when administered concomitantly with topical corticosteroids (TCS) in pediatric patients, 6 months to less than 6 years of age, with severe AD.

Clinical Study Identifier: TX201204

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.